Infex to present webinar on broader pipeline and growth strategy
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Webinar on Infex's Phase II lead respiratory drug, RESP-X
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…
Infex to present webinar on lead Phase II respiratory drug RESP-X
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the…
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…
Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
Listen to the podcast here Infex CEO Peter Jackson discusses the state of…